Petrelintide

Petrelintide is a long-acting amylin analog being developed for the treatment of obesity. It aims to enhance satiety and energy expenditure with once-weekly dosing.

In the literature, Petrelintide appears most often in work focused on appetite control, fat loss and weight loss. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.

Because it is catalogued here under powder peptides, Petrelintide also shows up in discussions of metabolism. Coverage across those topics varies widely in quality and depth, and much of it is early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.